Ockham Development Group, Inc. was acquired by Chiltern International Limited in July 2014. Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in oncology and a range of other therapeutic areas, together with global sourcing and FSP solutions. Chiltern’s 2,100 people work in more than 40 countries and offer expertise, engagement and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.